Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts(The Royal Melbourne Hospital), John F. Seymour(The Royal Melbourne Hospital), Martin Dunbar(AbbVie (United States)), Monali Desai(AbbVie (United States)), Jennifer R. Brown(Dana-Farber Cancer Institute), Lori A. Gressick(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), John M. Pagel(University of Washington), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Ming Zhu(AbbVie (United States)), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Elisa Cerri(AbbVie (United States)), Shekman Wong(AbbVie (United States)), Soham D. Puvvada(University of Arizona)
Cited by 1,887
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k